Publications (265) Publications de Jesús María Hernández Rivas

filter_list

2025

  1. ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker

    Leukemia, Vol. 39, Núm. 7, pp. 1650-1660

  2. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

    Blood, Vol. 145, Núm. 2, pp. 234-243

  3. Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients

    British Journal of Haematology

  4. Examining the Effects of the RUNX1 p.Leu43Ser Variant on FPD/AML Phenotypes Using a CRISPR/Cas9-Generated Knock-In Murine Model

    Biomolecules, Vol. 15, Núm. 5

  5. Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

    HemaSphere, Vol. 9, Núm. 10

  6. NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL

    Leukemia, Vol. 39, Núm. 8, pp. 1892-1904

  7. Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop

    Clinical Pharmacology and Therapeutics, Vol. 118, Núm. 3, pp. 551-560

  8. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

    Haematologica, Vol. 110, Núm. 5, pp. 1126-1140

  9. SAMHD1 dysfunction impairs DNA damage response and increases sensitivity to PARP inhibition in chronic lymphocytic leukemia

    Scientific Reports, Vol. 15, Núm. 1

  10. Sex Differences in Gut Microbiota and Their Relation to Arterial Stiffness (MIVAS Study)

    Nutrients , Vol. 17, Núm. 1

  11. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial

    The Lancet Haematology, Vol. 12, Núm. 7, pp. e529-e541

2024

  1. Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

    Cancer Genetics, Vol. 284-285, pp. 5-11

  2. Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis

    American Journal of Hematology

  3. Citogenética y biología molecular en hematología

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 149-186

  4. Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology

    PLoS Computational Biology, Vol. 20, Núm. 2

  5. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

    Haematologica, Vol. 109, Núm. 2, pp. 543-552

  6. Gut microbiota and its relationship with early vascular ageing in a Spanish population (MIVAS study)

    European Journal of Clinical Investigation, Vol. 54, Núm. 9

  7. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

  8. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  9. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere